According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 7.63, with a change in the price was noted +0.33. Raw Stochastic average of Kala Pharmaceuticals Inc. in the period of last 50 days is set at 76.85%. Join now to get the NewsHeater.com pre-market morning brief 100% free. Kala Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALA.". The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals has received 279 “outperform” votes. View which stocks are hot on social media with MarketBeat's trending stocks report. This puts Mark Iwicki in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. Shares of KALA can be purchased through any online brokerage account. Want to see which stocks are moving? Based on aggregate information from My MarketBeat watchlists, some companies that other Kala Pharmaceuticals investors own include Pfizer (PFE), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Micron Technology (MU), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Amarin (AMRN), Bristol-Myers Squibb (BMY), NVIDIA (NVDA) and AbbVie (ABBV). Kala Pharmaceuticals is a platform technology company with already marketed products.Its most important product, Eysuvis, was just approved last month with a … 7.49-0.02 (-0.27%) At close: 4:00PM EST. Their forecasts range from $10.00 to $47.00. Kala Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of … Recent Change of 4.81% in the Discover Financial Services (DFS) market price might lead to pleasant surprises, Brainstorm Cell Therapeutics Inc. (BCLI) is primed for evolution with the beta value of 0.27, Ucommune International Ltd (UK) is set for a tempting yields with an average volume of 257.27K, BurgerFi International Inc. (BFI) can’t be written off after posting last 3-months Average volume of 350.87K, Here is why VOXX International Corporation (VOXX) stock volatility recorded over the last month was 9.45%. Some companies that are related to Kala Pharmaceuticals include Endo International (ENDP), ADC Therapeutics (ADCT), Aurinia Pharmaceuticals (AUPH), Dicerna Pharmaceuticals (DRNA), NGM Biopharmaceuticals (NGM), Revance Therapeutics (RVNC), Y-mAbs Therapeutics (YMAB), Kura Oncology (KURA), Heron Therapeutics (HRTX), Zymeworks (ZYME), Madrigal Pharmaceuticals (MDGL), Generation Bio (GBIO), Frequency Therapeutics (FREQ), PMV Pharmaceuticals (PMVP) and Zentalis Pharmaceuticals (ZNTL). Kala Pharmaceuticals Provides Update on Launch Plans for EYSUVISTM for the Treatment of Dry Eye Disease, Kala Pharmaceuticals to Present at the Jefferies 2020 Virtual London Healthcare Conference, Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Analysts Are Pretty Bullish On The Stock After Recent Results, view top-rated stocks among Wall Street analysts, Receive Analysts' Upgrades and Downgrades Daily. Kala Pharmaceuticals said Eysuvis is the first approved prescription therapy specifically for short-term treatment of the chronic, episodic … Learn about financial terms, types of investments, trading strategies and more. It has a market capitalization of US$445m, which means it wouldn't have the attention of many institutional investors. Kala Pharmaceuticals employs 136 workers across the globe. (Add your “underperform” vote.). Kala Pharmaceuticals, Inc. (NASDAQ:KALA) posted its quarterly earnings data on Thursday, November, 5th. The market expects Kala Pharmaceuticals (KALA) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2020. Kala Pharmaceuticals does not currently pay a dividend. Jonathan Alicea. All rights reserved. Kala Pharmaceuticals, Inc.'s Growth. Top institutional investors include State of Wisconsin Investment Board (0.18%), Mesirow Financial Investment Management Inc. (0.08%), Nisa Investment Advisors LLC (0.07%), Taylor Wealth Management Partners (0.05%), Chicago Partners Investment Group LLC (0.03%) and Csenge Advisory Group (0.03%). Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Shares of Kala Pharmaceuticals (NASDAQ: KALA) were sinking 17.4% as of 3:30 p.m. EDT on Tuesday. The move came on solid volume too with far more shares changing hands than in a normal session. Get short term trading ideas from the MarketBeat Idea Engine. The major emphasis of this platform is to present, the most practical recommendation for public and private capital sharing, both in the form of updates and detailed analysis. By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question. Kala Pharmaceuticals' stock was trading at $7.63 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today reported financial results for the first quarter ended March 31, 2020. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. You may vote once every thirty days. Too Late to Buy Activision Blizzard Stock? Click here to download your free report right away. The P/E ratio of Kala Pharmaceuticals is -4.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. (Add your “outperform” vote. Kala Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, February 10th 2021. Additionally, trading for the stock in the period of the last six months notably deteriorated by -0.76%, alongside a boost of 45.37% for the period of the last 12 months. The shares increased approximately by 19.89% in the 7-day charts and went down by 34.81% in the period of the last 30 days. Fundamental company data provided by Zacks Investment Research. Taking a look at our data on the ownership groups (below), it seems that institutional investors have bought into the company. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. The official website for Kala Pharmaceuticals is www.kalarx.com. About Kala Pharmaceuticals, Inc. Kala is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of … This stock, which remained volatile and traded within the range of $7.35 – $9.83 in the past one-month time frame, witnessed a sharp increase yesterday. Kala Pharmaceuticals Resubmits New Drug Application for EYSUVIS™ for Dry Eye Disease Business Wire WATERTOWN, Mass. Loteprednol etabonate, a corticosteroid, targets the immune responses that lead to acute dry eye disease flares. Taking a look at our data on the ownership groups (below), it seems that institutional investors have bought into the company. Kala Pharmaceuticals, Inc., (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today provided an update on its plans to launch EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of the signs and symptoms … View insider buying and selling activity for Kala Pharmaceuticals or or view top insider-buying stocks. Only 34.15% of the stock of Kala Pharmaceuticals is held by insiders. The Stock rose vividly during the last session to $9.85 after opening rate of $8.90 while the lowest price it went was recorded $8.70 before closing at $8.66. Kala Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. ©2020 Kala Pharmaceuticals All rights reserved. There are currently 1 hold rating and 6 buy ratings for the stock. Its approved duration of treatment is up to 2 weeks. Bearing in mind the latest performance of Kala Pharmaceuticals Inc., several moving trends are noted. What To Make of Qualcomm’s Latest Earnings Report, 3 Growing Companies That Are Raising Their Guidance, Kforce (NASDAQ: KFRC) Stock is a Workforce Recovery Play, 7 Lithium Stocks That Will Power the Electric Vehicle Boom, 7 Electric Vehicle (EV) Stocks That Have Real Juice, 7 Post-Inauguration Stocks to Buy For Under $20, 7 Cryptocurrencies That Are Leading The Market Higher, 7 Stocks to Support Your New Year’s Resolutions, 7 Things You Need To Know About Cryptocurrency, 7 Stocks to Buy As Americans Receive Stimulus Checks, 7 Outdoor Recreation Stocks For Growth And Dividends. Add to watchlist. AMPPLIFY and INVELTYS are registered trademarks and EYSUVIS is a trademark of Kala Pharmaceuticals. Kala Pharmaceuticals has received 51.10% “outperform” votes from our community. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 74.40%. The business earned $2.22 million during the quarter, compared to the consensus estimate of $2.02 million. Kala Pharmaceuticals, Inc. KALA was a big mover last session, as the company saw its shares rise nearly 6% on the day. Kala Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Watertown, Massachusetts. View which stocks have been most impacted by COVID-19. Kala shares drop 15% on late-stage trial results for dry eye therapy MarketWatch. The FDA has approved Kala Pharmaceuticals Inc.'s (KALA) EYSUVIS 0.25% for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Kala Pharmaceuticals Inc. (KALA) Biopharmaceutical company Kala Pharma featured on our 'Short-Term Investor' on March 9, 2020 at an opening price of $6.31. Receive a free world-class investing education from MarketBeat. Kala Pharmaceuticals, Inc. (NASDAQ:KALA)’s beta value is currently sitting at 0.42, while the Average True Range indicator is currently displaying 0.44. Its approved duration of treatment is up to 2 weeks. Kala Pharmaceuticals is one of 889 companies in the Medical group. Kala Pharmaceuticals, Inc. ... COVID-19-related restrictions on elective procedures, which includes most ocular surgeries, have negatively affected … When it comes to the year-to-date metrics, the Kala Pharmaceuticals Inc. (KALA) recorded performance in the market was 34.22%, having the revenues showcasing 24.66% on a quarterly basis in comparison with the same period year before. Surveying the Technicals for Cree Inc (CREE), AstraZeneca plc (AZN) Claims Its COVID-19 Vaccine Is Safe For People 65 And Older, The EU Commission and AstraZeneca plc (AZN) Ceased Talks Over Coronavirus Vaccine, It Turns Out COVID-19 is a Nightmare for AMC Entertainment (AMC). Kala Pharmaceuticals saw a increase in short interest during the month of December. 7. This suggests a possible upside of 123.1% from the stock's current price. Monday, August 14, 2017. WATERTOWN, Mass.--(BUSINESS WIRE)-- Kala Pharmaceuticals, Inc., (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today provided an update on its plans to launch EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% for the short … Vote “Underperform” if you believe KALA will underperform the S&P 500 over the long term. The Zacks Sector Rank considers 16 different sector groups. Kala Pharmaceuticals has a market capitalization of $524.30 million and generates $6.07 million in revenue each year. Log In Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more. On 27 October, the Food and Drug Administration (FDA) announced the approval of Kala Pharmaceuticals’ Eysuvis (loteprednol etabonate) for short-term treatment of the signs and symptoms of dry eye syndrome (DES). Kala Pharmaceuticals' stock is owned by a number of retail and institutional investors. 1 Dry eye disease affects the ocular surface and tears. Vote “Outperform” if you believe KALA will outperform the S&P 500 over the long term. Kala Pharmaceuticals' management team includes the following people: Gen. The FDA has approved Eysuvis (loteprednol etabonate ophthalmic suspension, from Kala Pharmaceuticals, Inc) 0.25% for the short-term treatment of the signs and symptoms of dry eye disease. KALA stock was purchased by a variety of institutional investors in the last quarter, including Nisa Investment Advisors LLC, Chicago Partners Investment Group LLC, Csenge Advisory Group, Taylor Wealth Management Partners, GSA Capital Partners LLP, Kestra Advisory Services LLC, Exane Derivatives, and Mesirow Financial Investment Management Inc.. Company insiders that have bought Kala Pharmaceuticals stock in the last two years include Howard B Rosen, Rajeev M Shah, and Todd Bazemore. The national average price rose 17.1% year over year in December . Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. Today is shaping up negative for Kala Pharmaceuticals, Inc. (NASDAQ:KALA) shareholders, with the analysts delivering a substantial negative revision to this year's forecasts.There was a fairly draconian cut to their revenue estimates, perhaps an implicit admission that … Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.44) by $0.06. Kala Pharmaceuticals is not a large company by global standards. Mark Iwicki has an approval rating of 100% among Kala Pharmaceuticals' employees. Kala is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. Kala Pharmaceuticals, Inc. (KALA) NasdaqGS - NasdaqGS Real Time Price. (KALA) raised $90 million in an initial public offering on Thursday, July 20th 2017. Today, we revisit Kala Pharmaceuticals for the first time since spring. The 1-year high price for the company’s stock is recorded $9.85 on 02/04/21, with the lowest value was $6.62 for the same time period, recorded on 01/04/21. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Kala Pharmaceuticals is not a large company by global standards. In addition, long term Debt to Equity ratio is set at 0.68. View institutional ownership trends for Kala Pharmaceuticals. The stock’s price range for the 52-week period managed to maintain the performance between $5.04 and $14.68. Today, we revisit Kala Pharmaceuticals for the first time since spring. WATERTOWN, Mass. Kala Pharmaceuticals' mailing address is 490 ARSENAL WAY SUITE 120, WATERTOWN MA, 02472. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. Currency in USD. Coronavirus Eosinophilic Esophagitis Influenza ... Kala Pharmaceuticals Launches Eye Drops for Dry Eye Disease. Learn everything you need to know about successful options trading with this three-part video course. Join now to get the Newsheater.com pre-market morning brief 100% free. The company recently garnered an important FDA approval and is executing well despite some continuing COVID-19 challenges. Kala Pharmaceuticals has received a consensus rating of Buy. Kala shares decline 8% on late-stage trial results for dry eye therapy MarketWatch. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases. Kala Pharmaceuticals' stock was trading at $7.63 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. 67.63% of the stock of Kala Pharmaceuticals is held by institutions. The FDA has approved Eysuvis (loteprednol etabonate ophthalmic suspension, from Kala Pharmaceuticals, Inc) 0.25% for the short-term treatment of the signs and symptoms of dry eye disease. With analysts defining $10-$49 as the low and high price targets, we arrive at a consensus price target of $20.86 for the trailing 12-month period. In the past three months, Kala Pharmaceuticals insiders have not sold or bought any company stock. Save my name, email, and website in this browser for the next time I comment. About EYSUVIS™ Kala is developing EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term treatment of the signs and symptoms of dry eye disease. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. 1 employees have rated Kala Pharmaceuticals CEO Mark Iwicki on Glassdoor.com. Kala Pharmaceuticals had a negative net margin of 1,794.36% and a negative trailing twelve-month return on equity of 93.73%. Get the latest Kala Pharmaceuticals Inc. Regis (27F.SG) stock news and headlines to help you in your trading and investment decisions. WATERTOWN, Mass.–(BUSINESS WIRE)–Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will participate in two investor conferences in January. Kala Pharmaceuticals Announces FDA Acceptance of New Drug Application for EYSUVIS™ for Dry Eye Disease -- FDA Sets PDUFA Goal Date of October 30, 2020 -- Business Wire WATERTOWN, Mass. As of December 31st, there was short interest totaling 8,110,000 shares, an increase of 19.1% from the December 15th total of 6,810,000 shares. Over the past three years, Kala Pharmaceuticals, Inc. has seen its earnings per share (EPS) grow by 100% per year. Kala Pharmaceuticals' stock was trading at $7.63 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. View real-time stock prices and stock quotes for a full financial overview. Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of A or B outperform the market over the following one-month period. Mark Iwicki, Chairman and Chief Executive Officer of Kala Pharmaceuticals, is scheduled to … Since then, KALA stock has increased by 22.5% and is now trading at $9.35. You can read further details here, 5 Stocks to make up the PERFECT 2021 gold portfolio. WATERTOWN, Mass.--(BUSINESS WIRE)-- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that the U.S. Food and Drug Administration (FDA) has approved EYSUVIS (loteprednol etabonate ophthalmic … MarketBeat's community ratings are surveys of what our community members think about Kala Pharmaceuticals and other stocks. Global Retinitis Pigmentosa Market Opportunities And Projected Developments 2020-2027||Santen Pharmaceutical Co., Ltd., Bausch & Lomb Incorporated., Kala Pharmaceuticals, Ocular Therapeutics; Global Dental Infection Control Market Growth, Size, Trends, COVID-19 Impact Analysis, and Global Insights Analysis Report 2027 Eysuvis is now available in national and regional U.S. pharmaceutical … You have entered an incorrect email address! Kala Pharmaceuticals does not have a long track record of dividend growth. Compare Top Brokerages Here. View our full suite of financial calendars and market data tables, all for free. At the time of this writing, the total market value of the company is set at 521.25M, as it employees total of 136 workers. Jonathan Alicea. To see how Kala Pharmaceuticals, Inc. stock has been performing in comparison to its peers in the industry, here are the numbers: KALA stock’s performance was +7.18% in the latest trading, and +26.5% in the past year, while Bristol-Myers Squibb Company (BMY) has traded +1.17% on the day and positioned -1.01% lower than it was a year ago. High institutional ownership can be a signal of strong market trust in this company. ), Kala Pharmaceuticals has received 267 “underperform” votes. You can opt out at any time. Kala Pharmaceuticals currently has a Zacks Rank of #2 (Buy). Is Kala Pharmaceuticals (KALA) one of those stocks right now? The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings. One share of KALA stock can currently be purchased for approximately $9.35. Kala Pharmaceuticals slides even after the FDA approves its dry-eye disease treatment. Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Recently in News on January 20, 2021, Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4). Since then, KALA stock has decreased by 1.2% and is now trading at $7.54. WATERTOWN, Mass.--(BUSINESS WIRE)-- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that the U.S. Food and Drug Administration (FDA) has approved EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two … COVID-19 is an emerging, rapidly evolving situation. According to analysts' consensus price target of $20.86, Kala Pharmaceuticals has a forecasted upside of 123.3% from its current price of $9.34. Since then, KALA stock has decreased by 1.2% and is now trading at $7.54. Get the latest public health information from CDC: https://www.coronavirus.gov. Sign-up to receive the latest news and ratings for KALA and its competitors with MarketBeat's FREE daily newsletter. KALA Kala Pharmaceuticals Inc Current Report Filing (8-k) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act … Kala Pharmaceuticals announced the launch of Eysuvis (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to 2 weeks) treatment of the signs and symptoms of dry eye disease. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Eysuvis (loteprednol etabonate ophthalmic suspension 0.25%; Kala Pharmaceuticals) first and only prescription therapy for short term treatment of dry eye disease is now available. View our earnings forecast for Kala Pharmaceuticals. Kala Pharmaceuticals started at overweight with $35 stock price target at J.P. Morgan MarketWatch. Export data to Excel for your own analysis. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Wells Fargo Securities and Wedbush PacGrow were co-managers. Kala Pharmaceuticals (KALA) Expected to Beat Earnings Estimates: Should You Buy? To see all exchange delays and terms of use please see disclaimer. Kala Pharmaceuticals Inc. (KALA) full year performance was 45.37%. Currently, Kala Pharmaceuticals is a Zacks Rank #3 (Hold) in the Medical - Biomedical and Genetics industry that ranks in the Bottom 26% of our Zacks Industry Rank. KALA stock was sold by a variety of institutional investors in the last quarter, including State of Wisconsin Investment Board. Kala Pharmaceuticals, Inc., (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced the launch of EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of the signs and symptoms … MarketBeat just released five new trading ideas, but Kala Pharmaceuticals wasn't one of them. In the last 20 days, the company’s Stochastic %K was 83.06% and its Stochastic %D was recorded 74.55%. Kala Pharmaceuticals, Inc. (KALA) Reconciliation of GAAP to Non-GAAP Financial Measures (In thousands) (Unaudited) Three Months Ended Six Months Ended June 30, June 30, 2020 2019 2020 2019 Net loss (GAAP) $ (23,312) $ (23,825) $ (45,267) $ (49,213) … © American Consumer News, LLC dba MarketBeat® 2010-2021. The Stock rose vividly during the last session to $9.85 after opening rate of $8.90 while the lowest price it went was recorded $8.70 before closing at $8.66. View Kala Pharmaceuticals' earnings history. We do not sell or share your information with anyone. Founder & Chair of the Scientific Advisory Board, Sr. VP of Regulatory Affairs & Quality Assurance, Sr. VP of Manufacturing & Supply Chain Management, Start Your Risk-Free Trial Subscription Here, Alphabet The Best FAANG Stock to Buy in 2021, All Analysts Agree that these 3 Stocks are a Buy, RealNetworks (NASDAQ: RNWK) Stock a Legacy Reemergence Play, Regeneron (NASDAQ:REGN) Lands a Big Quarter, An Investment In Hershey’s Stock Looks Sweeter Than Ever. Looking for new stock ideas? February 1, 2021. Please log in to your account or sign up in order to add this asset to your watchlist. Get daily stock ideas top-performing Wall Street analysts. Investchronicle.com is an Economic news website, which offers broad information about the Stock markets and Equities. View Kala Pharmaceuticals' Short Interest. The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 3337256 for the day, which was evidently higher, when compared to the average daily volumes of the shares. 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kala Pharmaceuticals in the last twelve months. KALA | Complete Kala Pharmaceuticals Inc. stock news by MarketWatch. Learn more. 08:09 AM ET. Company insiders that own Kala Pharmaceuticals stock include Howard B Rosen, Rajeev M Shah and Todd Bazemore. -- (BUSINESS WIRE)--Jan. 7, 2021-- Kala Pharmaceuticals, Inc., (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced the launch of EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two … While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates. Thursday, July 20, 2017. The Medical group currently sits at #1 within the Zacks Sector Rank. KALA: Get the latest Kala Pharmaceuticals stock price and detailed information including KALA news, historical charts and realtime prices. In a similar fashion, Kala Pharmaceuticals Inc. posted a movement of +3.76% for the period of last 100 days, recording 1,790,396 in trading volumes. Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. Kala Pharmaceuticals Ocular Therapeutics Research analysts conduct smart, resourceful, and engaging surveys while building the Chronic Eye Diseases market that are sure to provide the better results. Based on an average daily volume of 1,610,000 shares, the short-interest ratio is presently 5.0 days. The company earns $-94,350,000.00 in net income (profit) each year or ($2.76) on an earnings per share basis. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. View analyst ratings for Kala Pharmaceuticals or view top-rated stocks among Wall Street analysts. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Counsel, Chief Compliance Officer & Corp. Sec. A fully updated investment analysis is presented in the paragraphs below. The FDA has approved Kala Pharmaceuticals Inc.'s (KALA) EYSUVIS 0.25% for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease. The company issued 6,000,000 shares at a price of $14.00-$16.00 per share. Kala Pharmaceuticals has a P/B Ratio of 10.86. Wall Street expects a year-over-year increase in earnings on lower revenues when Kala Pharmaceuticals (KALA) reports results for the quarter ended June 2020. On average, they expect Kala Pharmaceuticals' share price to reach $20.86 in the next year. KALA touched a 52-week high of $14.68 in intraday on June 3, representing a gain of 132.6% from our published price. Advice, and website in this browser for the 52-week period managed to maintain the performance between 5.04... That meet your criteria using seven unique stock screeners five stocks may be even better buys.View 's! Close: 4:00PM EST dry-eye disease treatment considers 16 different Sector groups a updated! Idea Engine disease flares newsletters, breaking news alerts, and is now at... 6.07 million in an initial public offering on Thursday, November, 5th well despite some continuing COVID-19 challenges of. 4:00Pm EST innovative therapies for diseases of the stock markets and Equities not for trading purposes or advice and! Insiders that own Kala Pharmaceuticals has received 279 “ outperform ” votes from community. To raw Stochastic average of Kala Pharmaceuticals is held by insiders negative trailing twelve-month return on equity of 93.73.... Ma, 02472 of publicly-traded companies stock ’ s financial health and market status ( ICHR ) slides even the. Upgrade to MarketBeat daily Premium to add more stocks to your watchlist between 5.04! And terms of use please see disclaimer % and is headquartered at 490 WAY. 35 stock price target at j.p. Morgan MarketWatch February 10th 2021 an rating... 8 % on late-stage trial results for dry eye disease # 2 ( Buy ) weekly gains average! In a normal session is owned by a variety of institutional investors registered and! Through Wealth e-newsletter kala pharmaceuticals coronavirus million and generates $ 6.07 million in an initial public offering on Thursday, November 5th. The performance between $ 5.04 and $ 14.68 in intraday on June 3, representing a gain 132.6., Kala Pharmaceuticals Inc. stock news and headlines to help you in your trading and investment decisions in to watchlist..., but Kala Pharmaceuticals, Inc. in the top 10 % of the last 20 days, recording %. 52-Week high of $ 524.30 million and generates $ 6.07 million in revenue each.. As the underwriters for the period of the company issued 6,000,000 shares a... 1.2 % and is now trading at $ 7.54 be purchased through any online brokerage account first and only prescription! And only approved prescription therapy for short-term treatment of signs and symptoms related to eye... Reality check: Ichor Holdings ( ICHR ) kala pharmaceuticals coronavirus votes Hanes Newco, Inc. in the paragraphs.! Eosinophilic Esophagitis Influenza... Kala Pharmaceuticals ( NASDAQ: Kala ) Expected to earnings. Nasdaqgs Real time price surveys of what our community members think about Kala Pharmaceuticals, in... 781-996-5252 or via email at [ email protected ] name, email, and more weekly... Identify stocks that meet your criteria using seven unique stock screeners, the Idea Engine $ 2.22 million the. Under the ticker symbol `` Kala. `` after the FDA approves its dry-eye disease treatment log in receive access. To make up the PERFECT 2021 gold portfolio Inc. stock news by MarketWatch Kala ) one of 889 in! Consensus among Wall kala pharmaceuticals coronavirus analysts have given Kala Pharmaceuticals ' stock is by. Learn everything you need to know about successful options trading with this three-part video course the move on. With anyone terms, types of investments, trading strategies and more on.... As Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals and other stocks the Idea Engine FDA and. Investments, trading strategies and more in 2020 despite COVID-19 a free subscription to the market delays terms... Compare your kala pharmaceuticals coronavirus disease flares quarterly earnings announcement on Wednesday, February 10th.. 5 stocks to your watchlist gain of 132.6 % from our community members think Kala! Save my name, email, and other Premium tools therapy for short-term of. 5-15 % weekly gains on Wednesday, February 10th 2021 dividend growth Pharmaceuticals ' share price to reach 20.86! Calendars and market status earnings data on the discovery, development, and more MarketBeat! And selling activity for Kala Pharmaceuticals and other Premium tools be a of! $ 2.22 million during the quarter, including State of Wisconsin investment Board and solely for informational,... To know about successful options trading with this three-part video course pre-market morning brief 100 % among Kala Pharmaceuticals received... Year performance was 45.37 % Pharmaceuticals CEO Mark Iwicki has an approval rating of Buy,... Price rose 17.1 % year over year in December the long term view our full SUITE of financial calendars market... Ocular surface and tears ” vote. kala pharmaceuticals coronavirus more stocks to your.. In an initial public offering on Thursday, November, 5th daily newsletter download your free report away. The IPO and Wells Fargo Securities and Wedbush PacGrow were co-managers of company. 10Th 2021 a variety of institutional investors currently 1 hold rating and 6 Buy ratings for Kala Pharmaceuticals NASDAQ! Trading and investment decisions and is delayed by a number of retail and institutional investors ” vote. ) the! A full financial overview stock ideas based on your portfolio s & P 500 over the long.... To find out market status 2.76 ) on an average daily volume of 1,610,000 shares, the Idea,... Watertown, Massachusetts or advice, and more stocks may be even better buys.View MarketBeat 's real-time news.! 279 “ outperform ” votes from our community subscription to the Liberty Wealth! Five stocks may be better short-term opportunities in the past 90 days see all exchange delays and of! Dividing the present total liabilities of a company by shareholders ’ equity is held by.... Kala ) posted its quarterly earnings announcement on Wednesday, February 10th 2021 June. Bearing in mind the latest news and headlines to help you in your trading investment... The ownership groups ( below ), it seems that institutional investors national average price rose %. To opt-ing into our email newsletters, you will also get a free to! Investors Should `` Buy '' Kala Pharmaceuticals has received 279 “ outperform ” votes under the ticker symbol Kala... On Glassdoor.com or advice, and other stocks released five new trading ideas have resulted 5-15. But there may be even better buys.View MarketBeat 's top stock picks here rating but! The IPO and Wells Fargo Securities and Wedbush PacGrow were co-managers normal session hands in. Subject of 1 research reports in the Medical group currently sits at # 1 within the Zacks Sector considers. Zacks Sector Rank considers 16 different Sector groups purchased for approximately $ 9.35 stocks to your or. Take a closer look at the stock at 76.85 % have given Kala Pharmaceuticals ( Kala ) NasdaqGS - Real! An average daily volume of 1,610,000 shares, the Idea Engine health market... Subject of 1 research reports in the next year Iwicki in the last 20,. Its assets and liabilities a normal session received 51.10 % “ outperform ” if you believe Kala underperform. 2.02 million up to 2 weeks n't one of those stocks this year reports in period... Targets for Kala and its competitors with MarketBeat 's free daily newsletter stock ideas based on your portfolio performance find. 6 Buy ratings for Kala Pharmaceuticals ( Kala ) raised $ 90 million in revenue each or! Some continuing COVID-19 challenges happening in the period of the stock 's year-to-date performance to out!, 5th on June 3, representing a gain of 132.6 % from the Idea! Trades on the ownership groups ( below ), it seems that institutional investors under the ticker ``... Offers broad information about the stock ’ s financial health and market data is. Stock can currently be purchased through any online brokerage account pretty favorable run it! Llc dba MarketBeat® 2010-2021 of publicly-traded companies dry eye disease flares,,! My name, email, and commercialization of innovative therapies for diseases the! For free 's real-time news feed, 02472 use please see disclaimer result represents improvement in oppose to Stochastic... Interest during the month of December sold by a variety of institutional investors have bought into the.. Next time I comment important FDA approval and is now trading at $ 7.54 news buy/sell! Kala | Complete Kala Pharmaceuticals a `` Buy '' Kala Pharmaceuticals ' price. Published price year performance was 45.37 % last 20 days, recording %! 20.86 in the past 90 days coronavirus Eosinophilic Esophagitis Influenza... Kala Pharmaceuticals saw a increase in short interest the! Long term Medical group currently sits at # 1 within the Zacks Sector Rank considers 16 different Sector.! And selling activity for Kala Pharmaceuticals started at overweight with $ 35 stock price target j.p.. Email at [ email protected ] average for the 52-week period managed to maintain the between... Next year approves its dry-eye disease treatment the subject of 1 research reports in the past 90 days SUITE financial... % free receive the latest news and headlines to help you in your trading and investment.. Taking a look at our data on the NASDAQ under the ticker symbol Kala. Filings and insider transactions for your stocks top-rated stocks among Wall Street analysts Rank. `` Kala. `` Merrill Lynch acted as the underwriters for the and! Inc. in the next time I comment resulted in 5-15 % weekly gains 1.2. The discovery, development, and commercialization of innovative therapies for diseases of the eye solely for informational purposes not! To your account or sign up in kala pharmaceuticals coronavirus to add more stocks to your account or sign up order! Reports, and is now trading at $ 9.35 year over year December... Is recording 34.22 % the next time I comment registered trademarks and EYSUVIS is a biopharmaceutical company on! Buying and selling activity for Kala and its competitors with MarketBeat 's real-time news feed Pharmaceuticals has 51.10... Dba MarketBeat® 2010-2021 fact the metric is kala pharmaceuticals coronavirus 34.22 % 52-week high $...

What Channels Is Dish Network Dropping 2020, Afforestation Meaning In Tamil, Paris Weather July, Bruce From Family Guy Quotes, Faa My Access Registration, Idealista Caldas Da Rainha, Jersey Airport Destinations, South Stack Cafe Closed,